Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 1

157MO - Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy


31 Mar 2022


Mini Oral session 1


Tumour Immunology;  Immunotherapy;  Translational Research

Tumour Site

Non-Small Cell Lung Cancer


Marta Casarrubios


Annals of Oncology (2022) 33 (suppl_2): S105-S110. 10.1016/annonc/annonc865


M. Casarrubios1, A. Cruz-Bermudez2, B. Sierra-Rodero1, E. Nadal3, M.A. Insa Molla4, M.R. Garcia Campelo5, C. Garcia Benito6, M. Domine Gomez7, M. Majem Tarruella8, D. Rodriguez Abreu9, A. Martinez10, J. De Castro Carpeno11, M. Cobo Dols12, G. Lopez Vivanco13, N. Vinolas Segarra14, I.C. Barneto Aranda15, S. Viteri16, B. Massuti Sureda17, M. Provencio Pulla18

Author affiliations

  • 1 Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Hospital Puerta de Hierro-Majadahonda, Majadahonda/ES
  • 2 Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Hospital Puerta de Hierro-Majadahonda, 28222 - Majadahonda/ES
  • 3 ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat/ES
  • 4 Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 5 University Hospital A Coruña, CHUAC, A Coruña/ES
  • 6 Hospital Universitario Alvaro Cunqueiro, 36312 - Vigo/ES
  • 7 IIS-Hospital Fundacion Jimenez Diaz, 28040 - Madrid/ES
  • 8 Hospital de la Santa Creu i Sant Pau, 8041 - Barcelona/ES
  • 9 Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria/ES
  • 10 Vall d'Hebron University Hospital, Barcelona/ES
  • 11 Hospital Universitario La Paz, 28046 - Madrid/ES
  • 12 Biomedical Research Institute of Málaga (IBIMA), Malaga/ES
  • 13 Hospital de Cruces, Barakaldo/ES
  • 14 Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 15 Hospital Universitario Reina Sofía, 14004 - Cordoba/ES
  • 16 UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona/ES
  • 17 Hospital General Universitario de Alicante, Alicante/ES
  • 18 University Hospital Puerta de Hierro Majadahonda, Majadahonda/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 157MO


Neoadjuvant chemoimmunotherapy (CI) for NSCLC is a promising strategy that yields high rates of complete pathological responses (CPR) that are associated with long-term survival. We analyzed the tumor microenvironment by using gene expression profiling in patients from NADIM trial to identify biomarkers predicting CPR.


RNAs extracted from whole sections of pre-treatment tumors of 14 patients enrolled in NADIM trial (NCT03081689) were sequenced using the Oncomine® Immune Response Research Assay panel. Differential-expressed genes between groups and pathway enrichment analysis were assessed using DESeq2 and Gene Set Enrichment Analysis (GSEA). CIBERSORTx was used to estimate the proportions of immune cells subtypes. Results were correlated with pathological response groups: complete (CPR, n=9) and non-complete (non-CPR, n=5) responders.


Up to 25 genes were identified as differentially expressed between CPR and non-CPR patients. Among them, 17 were upregulated in CPR compared to non-CPR: involved in type II interferon signalling (FASLG, CXCL13, CXCL10, CXCL9 and IFNG), NK cell markers (NCR1, KIR2DL3, GNLY) or lymphocyte enrichment (NKG7, GZMB) depicting a pro-inflammatory phenotype in pre-treatment tumour samples of CPR patients. Similarly, GSEA analysis revealed in CPR patients an up-regulation of pathways related to TCR co-expression, lymphocyte infiltrate, type II interferon signalling and antigen processing, as well as a downregulation of pathways related to tumour markers, proliferation or PD-1 signalling. Finally, CPR patients had a higher proportion of follicular helper T cells, activated NK cells, M1 macrophages, resting dendritic cells and absolute score of immune cells than non-CPR patients, being the proportion of M1 macrophages significantly different (p=0.002). The AUC ROC for response prediction based on IFNG, GZMB expression or M1 macrophages proportion was 1.000 (p=0.0027), 0.911 (p=0.0136) and 0.9778 (p=0.004), respectively.


In our study, a pro-inflammatory profile measured in the pre-treatment tissue by RNA-sequencing is associated with CPR following neoadjuvant CI in patients with stage IIIA NSCLC.

Clinical trial identification


Legal entity responsible for the study

Fundacion GECP.


Bristol Myers Squibb, Thermofisher provided reagents for RNA-seq. Spanish Lung Cancer Group promoted the NADIM study. ‘‘Instituto de Salud Carlos III’’ (ISCIII), European Regional Development Fund (ERDF), Ministry of Science and Innovation, European Social Fund (ESF) and Comunidad de Madrid supported authors’ contracts.


M. Provencio Pulla: Non-Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Non-Financial Interests, Institutional, Research Grant: Roche; Non-Financial Interests, Institutional, Research Grant: AstraZeneca; Non-Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Non-Financial Interests, Personal, Advisory Board: Roche; Non-Financial Interests, Personal, Advisory Board: AstraZeneca; Non-Financial Interests, Personal, Advisory Board: MSD; Non-Financial Interests, Personal, Advisory Board: Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.